Related Experiment Video
Updated: Oct 19, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
FOXD3-induced miR-133a blocks progression and metastasis of colorectal cancer through regulating UBA2
Yuanfang Cheng1, Yajuan Wang1, Yuanzun Cheng2
1Sanquan College of Xinxiang Medical University, west of Changjiang Avenue, Pingyuan New Area, Xinxiang City, Henan Province, China.
Abstract:
Background and Aim: Some studies have verified that miR-133a played an inhibitory role in several cancers. Whereas, the effect of miRNA-133a in colorectal cancer (CRC) has not been fully elucidated. Our study aims to confirm UBA2 as a direct target gene of miRNA-133a and explore the upstream modulatory molecules of miR-133a. In addition, their impacts on the biological characteristics of CRC cells were assessed. Methods: QRT-PCR analyzed miR-133a expression levels in colorectal cells including HCT116, SW48 cells and human normal colorectal cell line NCM460. A serial biological experiment assessed miR-133a effects on cell proliferation, migration, invasion and apoptosis capacities in HCT116 and SW48 cells. MiRNA targeting gene prediction and a dual luciferase assay were employed to confirm miR-133a-targeted UBA2. Transcription factors (TFs) FOXD3 was identified as an upstream regulator of miR-133a via JASPAR. The influence of miR-133a and FOXD3 on UBA2 expression was analyzed by qRT-PCR or western blot. Results: miR-133a was lowly expressed in CRC cells. High miRNA-133a expression suppressed the proliferation, migration, invasion and enhanced apoptosis capacities of CRC cells. MiR-133a targeted the UBA2 mRNA 3'UTR area and reduced UBA2 protein expression. We also unveiled that FOXD3 high-expression significantly raised miR-133a expression and diminished UBA2 expression. We also discovered that high miR-133a expression augmented the effects of elevated FOXD3 expression on CRC cell proliferation, migration and invasion, whereas, low miR-133a expression generated the opposite outcomes. Conclusion: FOXD3 induced miRNA-133a directly targeting UBA2 could affect the progression and growth of CRC.
Insights
MicroRNA-133a inhibits colorectal cancer (CRC) progression by targeting UBA2. FOXD3 enhances miR-133a, suppressing CRC cell growth and invasion.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- MicroRNA-133a (miR-133a) shows inhibitory roles in various cancers.
- The specific function of miR-133a in colorectal cancer (CRC) requires further elucidation.
- Understanding miR-133a's regulatory network is crucial for CRC targeted therapy.
Purpose of the Study:
- To confirm UBA2 as a direct target of miR-133a in CRC.
- To identify upstream molecules regulating miR-133a expression.
- To assess the impact of the miR-133a/UBA2 axis on CRC cell biological characteristics.
Main Methods:
- Quantitative real-time PCR (QRT-PCR) for gene expression analysis.
- Cell proliferation, migration, invasion, and apoptosis assays.
- Dual-luciferase assay to validate miR-133a targeting of UBA2.
- Bioinformatic analysis (JASPAR) to identify transcription factors.
Main Results:
- miR-133a was significantly downregulated in CRC cells.
- Overexpression of miR-133a inhibited CRC cell proliferation, migration, and invasion, while promoting apoptosis.
- miR-133a directly targets UBA2 mRNA, reducing its protein expression.
- FOXD3 acts as an upstream regulator, increasing miR-133a and decreasing UBA2 expression.
Conclusions:
- FOXD3-induced miR-133a directly targets UBA2, influencing CRC progression.
- The FOXD3/miR-133a/UBA2 pathway represents a potential therapeutic target for colorectal cancer.
- Modulating this pathway could offer novel strategies for CRC treatment.
Related Concept Videos
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

